Statistical design of personalized medicine interventions: The Clarification of Optimal Anticoagulation through Genetics (COAG) trial

Trials

Volumn 11, Issue , 2010, Pages

  French, Benjamin ^a   Joo, Jungnam ^b   Geller, Nancy L ^b   Kimmel, Stephen E ^a   Rosenberg, Yves ^b   Anderson, Jeffrey L ^c   Gage, Brian F ^d   Johnson, Julie A ^e   Ellenberg, Jonas H ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c INTERMOUNTAIN MEDICAL CENTER   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C9; GENE PRODUCT; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX 1; WARFARIN; ANTICOAGULANT AGENT;

ADULT; ALGORITHM; ANTICOAGULANT THERAPY; ARTICLE; CALCULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA POLYMORPHISM; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; GENE CONTROL; GENETIC VARIABILITY; GENOTYPE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHARMACOGENETICS; PREDICTIVE VALIDITY; PREDICTOR VARIABLE; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; STATISTICAL ANALYSIS; TREATMENT DURATION; TREATMENT PLANNING; METHODOLOGY; PERSONALIZED MEDICINE; STATISTICS;

ANTICOAGULANTS; DOUBLE-BLIND METHOD; GENOTYPE; HUMANS; INDIVIDUALIZED MEDICINE; PHARMACOGENETICS; RESEARCH DESIGN; SAMPLE SIZE; STATISTICS AS TOPIC; WARFARIN;

EID: 78349294600     PISSN: 17456215     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-11-108     Document Type: Article

References (28)

1. Terra SG, Johnson JA. Pharmacogenetics, pharmacogenomics, and cardiovascular therapies: The way forward. Am J Cardiovasc Drugs 2002, 2:287-296. 10.2165/00129784-200202050-00001, 14727958.
2. Wang SJ, O'Neill RT, Hung HM. Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset. Pharm Stat 2007, 6:227-244. 10.1002/pst.300, 17688238.
3. Sargent DJ, Conley BA, Allegra C, Collette L. Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 2005, 23:2020-2027. 10.1200/JCO.2005.01.112, 15774793.
4. Garcia D, Regan S, Crowther M, Hughes RA, Hylek EM. Warfarin maintenance dosing patterns in clinical practice: Implications for safer anticoagulation in the elderly population. Chest 2005, 127:2049-2056. 10.1378/chest.127.6.2049, 15947319.
5. Sanderson S, Emery J, Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: A HuGEnet systematic review and meta-analysis. Genet Med 2005, 7:97-104. 10.1097/01.GIM.0000153664.65759.CF, 15714076.
6. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, Blough DK, Thummel KE, Veenstra DL, Rettie AE. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005, 352:2285-2293. 10.1056/NEJMoa044503, 15930419.
7. Schelleman H, Chen J, Chen Z, Christie J, Newcomb CW, Brensinger CM, Price M, Whitehead AS, Kealey C, Thorn CF, Samaha FF, Kimmel SE. Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans. Clin Pharmacol Ther 2008, 84:332-339. 10.1038/clpt.2008.101, 2538606, 18596683.
8. Gage BF, Eby D, Johnson JA, Deych E, Rieder MJ, Ridker PM, Milligan PE, Grice G, Lenzini P, Rettie AE, Aquilante CL, Grosso L, Marsh S, Langaee T, Farnett LE, Voora D, Veenstra DL, Glynn RJ, Barrett A, McLeod HL. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 2008, 84:326-331. 10.1038/clpt.2008.10, 2683977, 18305455.
9. Lenzini P, Wadelius M, Kimmel S, Anderson JL, Jorgensen A, Pirmohamed M, Caldwell MD, Limdi N, Burmester JK, Dowd MB, Angchaisuksiri P, Bass AR, Chen J, Eriksson N, Rane A, Lindh JD, Carlquist JF, Horne BD, Grice G, Milligan PE, Eby C, Shin J, Kim H, Kurnik D, Stein CM, McMillin G, Pendleton RC, Berg RL, Deloukas P, Gage BF. Integration of genetic, clinical, and laboratory data to refine warfarin dosing. Clin Pharmacol Ther 2010, 87:572-578. 10.1038/clpt.2010.13, 20375999.
10. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993, 69:236-239.
11. Ellenberg JH. Intention-to-treat analysis. Encyclopedia of Biostatistics 1998, 2056-2060. New York: John Wiley & Sons, Armitage P, Colton T.
12. Fishman GS, Moore LR. A statistical evaluation of multiplicative congruential random number generators with modulus 231 - 1. J Amer Statist Assoc 1982, 77:129-136.
13. Anderson JL, Horne BD, Stevens SM, Grove AS, Barton S, Nicholas ZP, Kahn SF, May HT, Samuelson KM, Muhlestein JB, Carlquist JF, . Couma-Gen Investigators Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 2007, 116:2563-2570. 10.1161/CIRCULATIONAHA.107.737312, 17989110, Couma-Gen Investigators.
14. Dolan G, Smith LA, Collins S, Plumb JM. Effect of setting, monitoring intensity and patient experience on anticoagulation control: A systematic review and meta-analysis of the literature. Curr Med Res Opin 2008, 24:1479-1472.
15. The International Warfarin Pharmacogenetics Consortium Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009, 360:753-764. 10.1056/NEJMoa0809329, 2722908, 19228618, The International Warfarin Pharmacogenetics Consortium.
16. Caraco Y, Blotnick S, Muszkat M. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: A prospective randomized controlled study. Clin Pharmacol Ther 2008, 83:460-470. 10.1038/sj.clpt.6100316, 17851566.
17. Moyé LA. P-value interpretation and alpha allocation in clinical trials. Ann Epidemiol 1998, 8:351-357. 10.1016/S1047-2797(98)00003-9, 9708870.
18. Moyé LA, Deswal A. Trials within trials: Confirmatory subgroup analyses in controlled clinical experiments. Control Clin Trials 2001, 22:605-619. 10.1016/S0197-2456(01)00180-5, 11738119.
19. Coats AJ. CAPRICORN: A story of alpha allocation and beta-blockers in left ventricular dysfunction post-MI. Int J Cardiol 2001, 78:109-113. 10.1016/S0167-5273(01)00437-5, 11334653.
20. Alosh M, Hugue MF. A flexible strategy for testing subgroups and overall population. Stat Med 2009, 15:3-23.
21. Joo J, Geller NL, French B, Kimmel SE, Rosenberg Y, Ellenberg JE. Prospective alpha allocation in the Clarification of Optimal Anticoagulation through Genetics (COAG) trial. Clin Trials 2010, 7:597-604. 10.1177/1740774510381285, 20693186.
22. Lenzini PA, Grice GR, Milligan PE, Dowd MB, Subherwal S, Deych E, Eby CS, King CR, Porche-Sorbet RM, Murphy CV, Marchand R, Millican EA, Barrack RL, Clohisy JC, Kronquist K, Gatchel SK, Gage BF. Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients. J Thromb Haemost 2008, 6:1655-1662. 10.1111/j.1538-7836.2008.03095.x, 2920450, 18662264.
23. Lachin JM. Introduction to sample size determination and power analysis for clinical trials. Control Clin Trials 1981, 2:93-113. 10.1016/0197-2456(81)90001-5, 7273794.
24. Wittes J, Brittain E. The role of internal pilot studies in increasing the efficiency of clinical trials. Stat Med 1990, 9:65-71. 10.1002/sim.4780090113, 2345839.
25. Betensky RA, Tierney C. An examination of methods for sample size recalculation during an experiment. Stat Med 1997, 16:2587-2598. 10.1002/(SICI)1097-0258(19971130)16:22<2587::AID-SIM687>3.0.CO;2-5, 9403958.
26. Wittes J, Schabenberger O, Zucker D, Brittain E, Proschan M. Internal pilot studies I: Type I error rate of the naive t-test. Stat Med 1999, 18:3481-91. 10.1002/(SICI)1097-0258(19991230)18:24<3481::AID-SIM301>3.0.CO;2-C, 10611620.
27. Simon R. The use of genomics in clinical trial design. Clin Cancer Res 2008, 14:5984-5993. 10.1158/1078-0432.CCR-07-4531, 18829477.
28. Simon R, Maitouram A. Evaluating the efficiency of targeted designs for randomized clinical trials. Clin Cancer Res 2004, 10:6759-6763. 10.1158/1078-0432.CCR-04-0496, 15501951.